A new analysis presented at the American Heart Association’s (AHA) Scientific Sessions 2025 suggests that chronic melatonin use may not be as benign as widely believed
A new analysis presented at the American Heart Association’s (AHA) Scientific Sessions 2025 suggests that chronic melatonin use may not be as benign as widely believed
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
How can clinicians efficiently identify the root cause of excessive daytime sleepiness (EDS) in practice and better treat their patients? Nishi Bhopal, MD, shares her clinical tips.
How can clinicians efficiently identify the root cause of excessive daytime sleepiness (EDS) in practice and better treat their patients? Nishi Bhopal, MD, shares her clinical tips.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
A large, pooled analysis found that cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in adults with drug-resistant focal epilepsy.
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
The OPTION randomized clinical trial investigated whether intravenous tenecteplase administered in an extended time window after ischemic stroke onset benefits patients with non-large vessel occlusion (non-LVO) and evidence of salvageable...
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
Data from 2 phase 2 trials suggest that LT3001 (odatroltide), a novel dual-mechanism stroke therapy, may offer functional improvement in patients with acute ischemic stroke who cannot receive standard reperfusion treatments.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
A large nationwide cohort study found no evidence that preinjury antidepressant use increases short-term mortality, need for emergency brain surgery, or length of hospitalization following TBI.
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine.
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine.
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
